2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11259
    UPG-111 3090687-02-5
    UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system.
    UPG-111
  • HY-P11289
    Intermedin1-53 (Human) 98%
    Intermedin1-53 (Human) is a 53-aa human calcitonin family peptide that reduces the vulnerability of atherosclerotic plaques by inhibiting CHOP-mediated macrophage apoptosis and inflammasome.
    Intermedin1-53 (Human)
  • HY-P11297
    AC-SDKP-NH2 194484-75-8 98%
    AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research.
    AC-SDKP-NH2
  • HY-P11300
    YKYY 305370-00-7 98%
    YKYY, a antihypertensive peptide, is an Angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY can be isolated for the peptic digest of wakame Undaria pinnatifida. YKYY can be used for hypertension research.
    YKYY
  • HY-P11313
    Catestatin (rat) 98%
    Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na+ uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms.
    Catestatin (rat)
  • HY-P11314
    ABri 241145-90-4
    ABri, 34 amino acids long, is an Amyloid subunit with certain degree of N- and C-terminal heterogeneity and no sequence identity to any known amyloid protein. ABri is devoid of glycine, methionine, proline, aspartic acid, tryptophane, tyrosine and glutamine, featuring pyroglutamate at its N-terminus. ABri can be used for cerebral hemorrhages, ischemic infarction and Alzheimer disease research.
    ABri
  • HY-P11373
    α-Myosin (614-643) 176373-77-6
    α-Myosin (614-643) is a segment of polypeptide of the heavy chain of cardiac α-myosin. α-Myosin has a strong ability to induce autoimmune myocarditis.
    α-Myosin (614-643)
  • HY-P11384
    D-RGDW 144161-76-2 98%
    D-RGDW is an Arg-Gly-Asp (RGD) containing peptide. D-RGDW inhibits αIIbβ3 mediated platelet aggregation.
    D-RGDW
  • HY-P11411
    [D-Tyr27,36, D-Thr32]-Neuropeptide Y (27-36), rat
    [D-Tyr27,36, D-Thr32]-Neuropeptide Y (27-36), rat is a fragment analogue of a neuropeptide Y (NPY) with cardiovascular activity. [D-Tyr27,36, D-Thr32]-Neuropeptide Y (27-36), rat can induce profound and sustained hypotension in both hypertensive and normotensive rats and its antihypertensive effect is partly attributed to its activity on histamine receptor. [D-Tyr27,36, D-Thr32]-Neuropeptide Y (27-36), rat can be used for studying antihypertensive effects.
    [D-Tyr27,36, D-Thr32]-Neuropeptide Y (27-36), rat
  • HY-P11413
    PAI-1 139446-70-1 98%
    PAI-1 is a plasminogen activator inhibitor. PAI-1 is a member of the Ser Protease inhibitor superfamily with antiprotease activity. PAI-1 is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs).
    PAI-1
  • HY-P11416
    Ac-RGDS-NH2 122207-62-9
    Ac-RGDS-NH2, a tetrapeptide, is an integrin antagonist. Ac-RGDS-NH2 competitively binds to the GPIIb/IIIa receptor (Ki = 4.2 μM), inhibiting the binding of fibrinogen to platelets and thereby effectively suppressing platelet aggregation. Ac-RGDS-NH2 can be used for research on thrombosis.
    Ac-RGDS-NH2
  • HY-P11447
    COLIV-peptide 2121574-86-3
    COLIV-peptide is a type of specific binding peptide that can recognize and bind to Collagen Ⅳ, a key non-cellular component in atherosclerotic plaques. COLIV-peptide can be used for the study of atherosclerotic.
    COLIV-peptide
  • HY-P11467
    Gy-CATH 98%
    Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice.
    Gy-CATH
  • HY-P11468
    wkwkwNGwkwkw-NH2 98%
    wkwkwNGwkwkw-NH2 is a self-assembling β-hairpin antimicrobial peptide. wkwkwNGwkwkw-NH2 self-assembles into nanofibers. wkwkwNGwkwkw-NH2 interacts with LPS on the surface of the bacterial membrane and then disrupts the bacterial outer membrane, inner membrane, and cytoplasmic membrane to exert its antibacterial effects. wkwkwNGwkwkw-NH2 has high antibacterial activity and low hemolytic activity. wkwkwNGwkwkw-NH2 significantly reduces the S. aureus ATCC 25923 load at the skin wound. wkwkwNGwkwkw-NH2 displays synergistic effects when combined with antibiotics. wkwkwNGwkwkw-NH2 facilitates wound healing.
    wkwkwNGwkwkw-NH2
  • HY-P11487
    UTG-4 98%
    UTG-4 is a GLP-1R, GIPR, and GCGR agonist with EC50 values of 126.3 pM, 29.2 pM, and 250.2 pM, respectively. UTG-4 binds to HSA (Kd = 14.6 μM). UTG-4 effectively alleviates endothelial-mesenchymal transition. UTG-4 promotes weight loss, inhibits food intake, improves glucose tolerance, and has a significant anti-atherosclerotic effect.
    UTG-4
  • HY-P11495
    myr-RGT 1126379-15-4
    myr-RGT is a nutmeg acylated RGT peptide. myr-RGT can be used to inhibit extracellular signaling of integrin β3. myr-RGT can be used in the research of atherosclerosis and other related conditions.
    myr-RGT
  • HY-P11571
    CEI12 26046-92-4 98%
    CEI12 is an angiotensin I‐converting enzyme inhibitor (ACEI) peptide that can be isolated from aαs1‐casein peptide. CEI12 can be used for hypertension research.
    CEI12
  • HY-P11572
    NAVPITPTLNR 123432-25-7
    NAVPITPTLNR, a casein-derived peptide, is an angiotensin I‐converting enzyme (ACE) inhibitor. NAVPITPTLNR can be used for hypertension research.
    NAVPITPTLNR
  • HY-P11605
    Big endothelin-3 (Human, 1-41 amide) 133551-97-0
    Big endothelin-3 (Human, 1-41 amide) is a precursor molecule of the Endothelin-3 (ET-3) peptide composing of 41 amino acids.
    Big endothelin-3 (Human, 1-41 amide)
  • HY-P11619
    R2R01 98%
    R2R01 is a potent and selective relaxin family peptide receptor 1 (RXFP1) agonist with an EC50 of 0.34 nM. R2R01 activates RXFP1 to induce relaxin-like biological responses. R2R01 can increase heart rate in pithed and conscious rats. R2R01 can be used for the research of cardiovascular diseases.
    R2R01
Cat. No. Product Name / Synonyms Application Reactivity